<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The autoinflammatory diseases</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The autoinflammatory diseases</h1>
<div class="graphic"><div class="figure"><div class="ttl">The autoinflammatory diseases</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td><strong>Diseases of inflammasomes and related IL-1-family cytokines</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Pyrin inflammasome <ul> <li>Familial Mediterranean fever (FMF) </li> <li>Pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND) </li> <li>Hyperimmunoglobulin D syndrome (HIDS)</li> <li>Pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) </li> <li>Hyperzincemia/hypercalprotectinemia (HZ/HC)</li> <li>Periodic fever, immunodeficiency, and thrombocytopenia (PFIT) </li> </ul> </li> <li>NALP3/cryopyrin inflammasome <ul> <li>Familial cold autoinflammatory syndrome (FCAS) </li> <li>Muckle-Wells syndrome (MWS) </li> <li>Neonatal-onset multisystem inflammatory disorder (NOMID) </li> <li>Majeed syndrome/lipin 2 (LPIN2) </li> </ul> </li> <li>NLRC4 inflammasome <ul> <li>Autoinflammation with infantile enterocolitis (AIFEC) </li> </ul> </li> <li>NLRP12 inflammasome <ul> <li>Familial cold autoinflammatory syndrome 2 (FCAS2) </li> </ul> </li> <li>NLRP1 inflammasome <ul> <li>Multiple self-healing palmoplantar carcinoma (MSPC) </li> <li>Familial keratosis lichenoides chronica (FKLC) </li> <li>NLRP1-associated autoinflammation with arthritis and dyskeratosis (NAIAD) </li> </ul> </li> <li>AIM2 inflammasome (none described) </li> <li>Noncanonical inflammasome (none described) </li> <li>Deficiency of the IL1 receptor antagonist (DIRA) </li> <li>Deficiency of the IL-36 receptor antagonist (DITRA) </li> </ul> </td> </tr> <tr> <td><strong>Diseases of interferon production and signaling</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Impaired degradation or processing of endogenous nucleic acids <ul> <li>AGS1 - Three prime repair exonuclease 1 (TREX1) </li> <li>AGS2 - Ribonuclease H2 endonuclease complex subunit B (RNASEH2B) </li> <li>AGS3 - Ribonuclease H2 endonuclease complex subunit C (RNASEH2C) </li> <li>AGS4 - Ribonuclease H2 endonuclease complex subunit A (RNASEH2A) </li> <li>AGS5 - SAM domain and HD domain 1 (SAMHD1) </li> <li>AGS6 - Adenosine deaminase acting on RNA 1 (ADAR1) </li> <li>DNase II </li> <li>Polyribonucleotide nucleotidyltransferase 1 (PNPT1) - Polynucleotide phosphorylase (PNPase) </li> </ul> </li> <li>Enhanced nucleic acid sensing <ul> <li>Stimulator of interferon genes (STING) </li> <li>AGS7 - Interferon-induced helicase C domain-containing protein 1 (IFIH1), encoding melanoma differentiation-associated protein 5 (MDA5) </li> </ul> </li> <li>Proteasome dysfunction <ul> <li>Chronic atypical neutrophilic dermatitis with lipodystrophy and elevated temperature (CANDLE) - Multiple genes </li> </ul> </li> <li>Amplified interferon receptor signaling <ul> <li>Ubiquitin-specific peptidase 18 (UPS18) - Pseudo-toxoplasmosis, other (syphilis), rubella, cytomegalovirus, herpes simplex virus (TORCH) syndrome </li> <li>ISG15 ubiquitin-like modifier (ISG15) </li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>Diseases of NFkB and/or TNF activity</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Haploinsufficiency of A20/TNF-alpha-induced protein 3 (TNFAIP3) </li> <li>Nucleotide-binding oligomerization domain protein 2 (NOD2) - Blau syndrome </li> <li>TNF receptor-associated periodic syndrome (TRAPS) </li> <li>Deficiency of adenosine deaminase 2 (DADA2) </li> <li>NFkB essential modulator (NEMO) </li> <li>Rel A haploinsufficiency </li> <li>Disorders of linear ubiquitination <ul> <li>OTULIN-related autoinflammatory syndrome (ORAS; ie, otulipenia) </li> <li>Deficiency of linear ubiquitin chain assembly complex (LUBAC) - Heme-oxidized IRP2 ubiquitin ligase 1 (HOIL-1L), HOIL-1 interacting protein (HOIP) </li> </ul> </li> <li>TNF receptor-associated periodic syndrome 11 (TRAPS11) - TNF receptor superfamily member 11A (TNFRSF11A) </li> <li>Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) </li> </ul> </td> </tr> <tr> <td><strong>Autoinflammation mediated by miscellaneous mechanisms</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Coatomer protein complex subunit alpha (COPA) syndrome </li> <li>PLCG2-associated antibody deficiency and immune dysregulation (PLAID)/autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID) </li> <li>Sideroblastic anemia with B cell immunodeficiency, periodic fevers, and developmental delay (SIFD) </li> <li>Disorders of complement activation </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">IL: interleukin; NALP3: NACHT, LRR, and PYD domains-containing protein 3; NLRC4: Nod-like receptor family, caspase recruitment domain-containing 4; NLRP: nucleotide-binding oligomerization domain-like receptor family pyrin domain containing; AIM2: absent in melanoma 2; AGS: Aicardi-Gouti√®res syndrome; NFkB: nuclear factor kappa-light-chain-enhancer of activated B cells; TNF: tumor necrosis factor; OTULIN: OTU deubiquitinase with linear linkage specificity; PLCG2: phospholipase C gamma 2.</div><div class="graphic_reference">Courtesy of Peter A Nigrovic, MD.</div><div id="graphicVersion">Graphic 130004 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
